Integrated Research Facility at Fort Detrick

德特里克堡综合研究设施

• 批准号: 8946625
• 负责人: Peter Jahrling
• 金额: $ 3341.46万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8946625
• 关键词: Aerosols; African; Anatomy; Animal Model; Animals; Biological; Cell Culture Techniques; Centers for Disease Control and Prevention (U.S.); Clinical; Clinical Pathology; Clinical Research; Communicable Diseases; Confocal Microscopy; Containment; Disease; Ebola virus; Electron Microscopy; Emerging Communicable Diseases; Immunology; Infection; Infectious Diseases Research; Influenza; Intramural Research; Laboratories; Maryland; Medical; Medical Imaging; Medical Research; Mission; Modality; Outcome; Pathology; Patients; Primates; Public Health; Reporting; Research; Research Institute; Rodent; Role; Science; United States; United States National Institutes of Health; Vaccines; Viral; biodefense; improved; novel; pathogen; programs; research facility; tool

For FY14, the Integrated Research Facility in the Division of Clinical Research has significantly increased the level of research facilitation that it provides. Primarily, this support has been directed to facilitating the biodefense and emerging infectious disease research of the Emerging Viral Pathogens section in the Division of Intramural Research, reported separately. In addition, core capabilities of the IRF have been established to include clinical pathology, anatomic pathology, electron microscopy, confocal microscopy, immunology, and cell culture. Rodents were introduced into the facility in November 2012, followed by primates in December of the same year. Medical imaging using all four modalities on uninfected animals was initiated in January 2013 followed by infections of non-Select Agents in March 2013. Aerosol infectivity studies began in April 2013, followed by influenza and MERS in July 2013. Research involving Ebola virus including West African strains was initiated in August 2014.

对于2014财年，临床研究部门的综合研究机构显着提高了其提供的研究促进水平。 首先，这种支持是针对新兴病毒病原体部分在壁内研究中促进的生物探讨和新兴的传染病研究。此外，已经建立了IRF的核心能力，包括临床病理，解剖病理学，电子显微镜，共聚焦显微镜，免疫学和细胞培养。 啮齿动物于2012年11月被引入该设施，随后是同年12月的灵长类动物。 2013年1月开始使用未感染动物的所有四种方式进行医学成像，然后于2013年3月感染非选择药物。气雾剂感染性研究始于2013年4月，随后在2013年7月进行了流感，随后是涉及埃博拉病毒的研究，包括埃博拉病毒在内，包括西非菌株在内的埃博拉病毒，于2014年8月发起。